Statins, the inhibitors of HMGCR, are widely used first-line drugs to lower plasma cholesterol and significantly decreased the risk of cardiovascular disease (CVD) and HCC in some patients. This evidence concerns the gene HMGCR and hepatocellular carcinoma.